Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced o...

Por Brose, Marcia S, Nutting, Christopher M, Sherman, Steven I, Shong, Young Kee, Smit, Johannes WA, Reike, Gerhard, Chung, John, Kalmus, Joachim, Kappeler, Christian, Schlumberger, Martin
Publicado em 2011

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study

Por Van Cutsem, Eric, Martinelli, Erika, Cascinu, Stefano, Sobrero, Alberto, Banzi, Maria, Seitz, Jean‐François, Barone, Carlo, Ychou, Marc, Peeters, Marc, Brenner, Baruch, Hofheinz, Ralf Dieter, Maiello, Evaristo, André, Thierry, Spallanzani, Andrea, Garcia‐Carbonero, Rocio, Arriaga, Yull E., Verma, Udit, Grothey, Axel, Kappeler, Christian, Miriyala, Ashok, Kalmus, Joachim, Falcone, Alfredo, Zaniboni, Alberto
Publicado no Oncologist (2018)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial

Por Xu, Jianming, Xu, Rui‐Hua, Qin, Shukui, Pan, Hongming, Bai, Yuxian, Chi, Yihebali, Wang, Liwei, Bi, Feng, Cheng, Ying, Liu, Tianshu, Ma, Dong, Shen, Lin, Ba, Yi, Liang, Jun, Wang, Xin, Yau, Thomas C C, Ma, Brigette B, Yeh, Kun‐Huei, Lin, Jen‐Kou, Kappeler, Christian, Shapiro, JoAnn, Kalmus, Joachim, Li, Jin
Publicado no J Gastroenterol Hepatol (2020)